Discovery of human antibodies against sea snake venom phospholipase A2s from Aipysurus laevis

Line P. Lauridsen; Andreas Hougaard Laustsen; Mikael Rørdam Andersen; Brian Lohse

Discovery of human antibodies against sea snake venom phospholipase A₂s from Aipysurus laevis

Line P. Lauridsen, Andreas Hougaard Laustsen, Mikael Rørdam Andersen, Brian Lohse

University of Copenhagen

Research output: Contribution to conference › Poster › Research › peer-review

253 Downloads (Orbit)

Abstract

Snakebite is one of the world’s most neglected tropical diseases, with an estimated 5.5 million bites peryear, resulting in 125.000 deaths. The only current treatment for snakebite envenoming is antiserumderived from the blood of immunized mammals (typically horses). These antisera are expensive toproduce and carry a high risk of causing hyper-allergic reactions in human recipients due to theirheterologous origin. Here we report the discovery of human scFvs against Aipysurus laevis toxins.

Original language	English
Publication date	2016
Number of pages	1
Publication status	Published - 2016
Event	14th Protein.DTU Workshop: Applied Protein Science - Technical University of denmark, Kgs. Lyngby, Denmark Duration: 9 May 2016 → 9 May 2016 Conference number: 14

Workshop

Workshop	14th Protein.DTU Workshop
Number	14
Location	Technical University of denmark
Country/Territory	Denmark
City	Kgs. Lyngby
Period	09/05/2016 → 09/05/2016

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

Discovery of human antibodies against sea snake venom phospholipase A2s from Aipysurus laevisFinal published version, 1.4 MB

OpenUrl availability

Full text

Cite this

@conference{29e53a3d4148460d938320a3e3b74efb,

title = "Discovery of human antibodies against sea snake venom phospholipase A2s from Aipysurus laevis",

abstract = "Snakebite is one of the world{\textquoteright}s most neglected tropical diseases, with an estimated 5.5 million bites peryear, resulting in 125.000 deaths. The only current treatment for snakebite envenoming is antiserumderived from the blood of immunized mammals (typically horses). These antisera are expensive toproduce and carry a high risk of causing hyper-allergic reactions in human recipients due to theirheterologous origin. Here we report the discovery of human scFvs against Aipysurus laevis toxins.",

author = "Lauridsen, \{Line P.\} and Laustsen, \{Andreas Hougaard\} and Andersen, \{Mikael R{\o}rdam\} and Brian Lohse",

year = "2016",

language = "English",

note = "14th Protein.DTU Workshop : Applied Protein Science ; Conference date: 09-05-2016 Through 09-05-2016",

}

TY - CONF

T1 - Discovery of human antibodies against sea snake venom phospholipase A2s from Aipysurus laevis

AU - Lauridsen, Line P.

AU - Laustsen, Andreas Hougaard

AU - Andersen, Mikael Rørdam

AU - Lohse, Brian

N1 - Conference code: 14

PY - 2016

Y1 - 2016

N2 - Snakebite is one of the world’s most neglected tropical diseases, with an estimated 5.5 million bites peryear, resulting in 125.000 deaths. The only current treatment for snakebite envenoming is antiserumderived from the blood of immunized mammals (typically horses). These antisera are expensive toproduce and carry a high risk of causing hyper-allergic reactions in human recipients due to theirheterologous origin. Here we report the discovery of human scFvs against Aipysurus laevis toxins.

AB - Snakebite is one of the world’s most neglected tropical diseases, with an estimated 5.5 million bites peryear, resulting in 125.000 deaths. The only current treatment for snakebite envenoming is antiserumderived from the blood of immunized mammals (typically horses). These antisera are expensive toproduce and carry a high risk of causing hyper-allergic reactions in human recipients due to theirheterologous origin. Here we report the discovery of human scFvs against Aipysurus laevis toxins.

M3 - Poster

T2 - 14th Protein.DTU Workshop

Y2 - 9 May 2016 through 9 May 2016

ER -